Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Citizen Meds vs Maves

Citizen Meds
Graded #254

Lower grade

vs+7.8999999999999915
Maves
Graded #91

Higher grade

The verdict

Maves takes it — 71.6/100 to 63.7/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +13
70
83
Dose & formulationMaves +11
54
65
Clinical oversightCitizen Meds +3
79
76
Labs & monitoringEven
52
52
FulfillmentMaves +25
62
87
Contract termsEven
55
55
Citizen Meds · left barMaves · right bar

The numbers

MetricCitizen MedsMaves
WeighScore63.7/10071.6/100
GradeCC
Scorecard rank#254#91
Semaglutide$125/mo (0.25 mg dose, compounded)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$185/mo (2.5 mg dose, first-month rate, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Citizen Meds

Graded #254 · C

Strengths

  • Semaglutide confirmed from product listings
  • New-patient discount available (code NEWPATIENT10)

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • State availability not disclosed
  • About page returns a 404
  • Limited overall transparency
Maves

Graded #91 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard